Epigenetic alterations and advancement of lymphoma treatment
Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2024-05, Vol.103 (5), p.1435-1454 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1454 |
|---|---|
| container_issue | 5 |
| container_start_page | 1435 |
| container_title | Annals of hematology |
| container_volume | 103 |
| creator | Zhuang, Shuhui Yang, Zhaobo Cui, Zhuangzhuang Zhang, Yuanyuan Che, Fengyuan |
| description | Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone modifications, non-coding RNA regulation, and RNA modifications play crucial roles in lymphoma pathogenesis. Epigenetic modification–targeting drugs have exhibited therapeutic efficacy and tolerability in both monotherapy and combination lymphoma therapy. This review discusses pathogenic mechanisms and potential epigenetic therapeutic targets in common lymphomas, offering new avenues for lymphoma diagnosis and treatment. We also discuss the shortcomings of current lymphoma treatments, while suggesting potential areas for future research, in order to improve the prediction and prognosis of lymphoma. |
| doi_str_mv | 10.1007/s00277-023-05395-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2851143590</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2851143590</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-ce185ff2c2574189e75891d48ca8fbe5d61285b64229ba2c37151eb141fe96803</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozjj6B1xIwY2bah5Nm4AbGcYHDLjRdUjT27FDXyapMPPrzdhRwYXZhCTfOefmIHRO8DXBOLtxGNMsizFlMeZM8nh7gKYkYTQcRXKIplgyGfOwJujEuTXGhIqEHqMJy7ggGWFTdLvoqxW04CsT6dqD1b7qWhfptoh08aFbAw20PurKqN40_VvX6Mhb0H53e4qOSl07ONvvM_R6v3iZP8bL54en-d0yNiHIxwaI4GVJDeVZQoSEkC5JkQijRZkDL9IwF8_ThFKZaxpEhBPISUJKkKnAbIauRt_edu8DOK-ayhmoa91CNzgV1CT8m8sdevkHXXeDbcN0imGWpSnjRAaKjpSxnXMWStXbqtF2owhWu27V2K0K3aqvbtU2iC721kPeQPEj-S4zAGwEXHhqV2B_s_-x_QRPaoOm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3037663519</pqid></control><display><type>article</type><title>Epigenetic alterations and advancement of lymphoma treatment</title><source>Springer Online Journals Complete</source><creator>Zhuang, Shuhui ; Yang, Zhaobo ; Cui, Zhuangzhuang ; Zhang, Yuanyuan ; Che, Fengyuan</creator><creatorcontrib>Zhuang, Shuhui ; Yang, Zhaobo ; Cui, Zhuangzhuang ; Zhang, Yuanyuan ; Che, Fengyuan</creatorcontrib><description>Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone modifications, non-coding RNA regulation, and RNA modifications play crucial roles in lymphoma pathogenesis. Epigenetic modification–targeting drugs have exhibited therapeutic efficacy and tolerability in both monotherapy and combination lymphoma therapy. This review discusses pathogenic mechanisms and potential epigenetic therapeutic targets in common lymphomas, offering new avenues for lymphoma diagnosis and treatment. We also discuss the shortcomings of current lymphoma treatments, while suggesting potential areas for future research, in order to improve the prediction and prognosis of lymphoma.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-023-05395-z</identifier><identifier>PMID: 37581713</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antigens ; Apoptosis ; Cell growth ; DNA methylation ; Drug resistance ; Epigenetics ; Epstein-Barr virus ; FDA approval ; Federal regulation ; Gene expression ; Genomes ; Hematology ; Hospitals ; Lymphocytes ; Lymphoma ; Medicine ; Medicine & Public Health ; Mortality ; Oncology ; Pathogenesis ; Review Article ; T cell receptors ; Transcription factors ; Tumors</subject><ispartof>Annals of hematology, 2024-05, Vol.103 (5), p.1435-1454</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-ce185ff2c2574189e75891d48ca8fbe5d61285b64229ba2c37151eb141fe96803</citedby><cites>FETCH-LOGICAL-c375t-ce185ff2c2574189e75891d48ca8fbe5d61285b64229ba2c37151eb141fe96803</cites><orcidid>0009-0007-7675-5863</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-023-05395-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-023-05395-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37581713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhuang, Shuhui</creatorcontrib><creatorcontrib>Yang, Zhaobo</creatorcontrib><creatorcontrib>Cui, Zhuangzhuang</creatorcontrib><creatorcontrib>Zhang, Yuanyuan</creatorcontrib><creatorcontrib>Che, Fengyuan</creatorcontrib><title>Epigenetic alterations and advancement of lymphoma treatment</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone modifications, non-coding RNA regulation, and RNA modifications play crucial roles in lymphoma pathogenesis. Epigenetic modification–targeting drugs have exhibited therapeutic efficacy and tolerability in both monotherapy and combination lymphoma therapy. This review discusses pathogenic mechanisms and potential epigenetic therapeutic targets in common lymphomas, offering new avenues for lymphoma diagnosis and treatment. We also discuss the shortcomings of current lymphoma treatments, while suggesting potential areas for future research, in order to improve the prediction and prognosis of lymphoma.</description><subject>Antigens</subject><subject>Apoptosis</subject><subject>Cell growth</subject><subject>DNA methylation</subject><subject>Drug resistance</subject><subject>Epigenetics</subject><subject>Epstein-Barr virus</subject><subject>FDA approval</subject><subject>Federal regulation</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Hematology</subject><subject>Hospitals</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Pathogenesis</subject><subject>Review Article</subject><subject>T cell receptors</subject><subject>Transcription factors</subject><subject>Tumors</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kEtLxDAUhYMozjj6B1xIwY2bah5Nm4AbGcYHDLjRdUjT27FDXyapMPPrzdhRwYXZhCTfOefmIHRO8DXBOLtxGNMsizFlMeZM8nh7gKYkYTQcRXKIplgyGfOwJujEuTXGhIqEHqMJy7ggGWFTdLvoqxW04CsT6dqD1b7qWhfptoh08aFbAw20PurKqN40_VvX6Mhb0H53e4qOSl07ONvvM_R6v3iZP8bL54en-d0yNiHIxwaI4GVJDeVZQoSEkC5JkQijRZkDL9IwF8_ThFKZaxpEhBPISUJKkKnAbIauRt_edu8DOK-ayhmoa91CNzgV1CT8m8sdevkHXXeDbcN0imGWpSnjRAaKjpSxnXMWStXbqtF2owhWu27V2K0K3aqvbtU2iC721kPeQPEj-S4zAGwEXHhqV2B_s_-x_QRPaoOm</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Zhuang, Shuhui</creator><creator>Yang, Zhaobo</creator><creator>Cui, Zhuangzhuang</creator><creator>Zhang, Yuanyuan</creator><creator>Che, Fengyuan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0007-7675-5863</orcidid></search><sort><creationdate>20240501</creationdate><title>Epigenetic alterations and advancement of lymphoma treatment</title><author>Zhuang, Shuhui ; Yang, Zhaobo ; Cui, Zhuangzhuang ; Zhang, Yuanyuan ; Che, Fengyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-ce185ff2c2574189e75891d48ca8fbe5d61285b64229ba2c37151eb141fe96803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antigens</topic><topic>Apoptosis</topic><topic>Cell growth</topic><topic>DNA methylation</topic><topic>Drug resistance</topic><topic>Epigenetics</topic><topic>Epstein-Barr virus</topic><topic>FDA approval</topic><topic>Federal regulation</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Hematology</topic><topic>Hospitals</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Pathogenesis</topic><topic>Review Article</topic><topic>T cell receptors</topic><topic>Transcription factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhuang, Shuhui</creatorcontrib><creatorcontrib>Yang, Zhaobo</creatorcontrib><creatorcontrib>Cui, Zhuangzhuang</creatorcontrib><creatorcontrib>Zhang, Yuanyuan</creatorcontrib><creatorcontrib>Che, Fengyuan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhuang, Shuhui</au><au>Yang, Zhaobo</au><au>Cui, Zhuangzhuang</au><au>Zhang, Yuanyuan</au><au>Che, Fengyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epigenetic alterations and advancement of lymphoma treatment</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>103</volume><issue>5</issue><spage>1435</spage><epage>1454</epage><pages>1435-1454</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone modifications, non-coding RNA regulation, and RNA modifications play crucial roles in lymphoma pathogenesis. Epigenetic modification–targeting drugs have exhibited therapeutic efficacy and tolerability in both monotherapy and combination lymphoma therapy. This review discusses pathogenic mechanisms and potential epigenetic therapeutic targets in common lymphomas, offering new avenues for lymphoma diagnosis and treatment. We also discuss the shortcomings of current lymphoma treatments, while suggesting potential areas for future research, in order to improve the prediction and prognosis of lymphoma.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37581713</pmid><doi>10.1007/s00277-023-05395-z</doi><tpages>20</tpages><orcidid>https://orcid.org/0009-0007-7675-5863</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2024-05, Vol.103 (5), p.1435-1454 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2851143590 |
| source | Springer Online Journals Complete |
| subjects | Antigens Apoptosis Cell growth DNA methylation Drug resistance Epigenetics Epstein-Barr virus FDA approval Federal regulation Gene expression Genomes Hematology Hospitals Lymphocytes Lymphoma Medicine Medicine & Public Health Mortality Oncology Pathogenesis Review Article T cell receptors Transcription factors Tumors |
| title | Epigenetic alterations and advancement of lymphoma treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T15%3A49%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epigenetic%20alterations%20and%20advancement%20of%20lymphoma%20treatment&rft.jtitle=Annals%20of%20hematology&rft.au=Zhuang,%20Shuhui&rft.date=2024-05-01&rft.volume=103&rft.issue=5&rft.spage=1435&rft.epage=1454&rft.pages=1435-1454&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-023-05395-z&rft_dat=%3Cproquest_cross%3E2851143590%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3037663519&rft_id=info:pmid/37581713&rfr_iscdi=true |